<?xml version="1.0" encoding="UTF-8"?>
<p>Intravenously administered steroids have been recommended for selected non-TB patients with ARDS, preferably in a trial setting [
 <xref rid="C86" ref-type="bibr">86</xref>, 
 <xref rid="C161" ref-type="bibr">161</xref>]. However, the role of steroids to reduce ARDS in TB patients is limited as data of good quality to support the use of steroids outside the treatment of TB meningitis is scarce [
 <xref rid="C163" ref-type="bibr">163</xref>]. Evidence on the use of steroids in COVID-19 is awaited.
</p>
